EGFR and non-small cell lung carcinoma: A multi-institution single arm phase II trial showed that the median progression free survival (PFS) of Gefitinib (250mg/d) combined with chest radiation therapy for locally advanced NSCLC patients with EGFR sensitive mutations was 18.6 months, the objective response rate (ORR) was 81.5%, and the overall survival (OS) was 61.1 months.